DX
DXB.AU Dimerix Ltd
- Market cap
- AUD 126M
- P/E
- -
- P/B
- 24.45x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is DXB.AU undervalued?
Graham numberThe Graham number of Dimerix Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dimerix Ltd fundamental analysis
3 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 1/1
Return on assets (-50.9%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-110.0%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 390.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (24.4x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Dimerix Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Full company profileDimerix Ltd financial statements
Dimerix Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 555K | 845K | 1.45M | 2.34M | 4.44M | 6.46M | 36.8K | 583K | 1.25M | 4.35M |
| Gross Profit | 553K | 839K | 1.44M | 2.33M | 4.40M | 6.41M | 36.8K | 583K | 1.25M | 4.21M |
| Operating Income | -2.31M | -4.17M | -4.33M | -6.92M | -10.9M | -10.5M | -22.8M | -25.2M | -36.3M | -37.2M |
| EBITDA | -2.29M | -4.14M | -4.31M | -6.82M | -10.0M | -16.5M | -22.7M | -25.0M | -36.2M | -37.0M |
| Net Income | -1.76M | -3.32M | -2.89M | -4.49M | -6.37M | -10.5M | -13.8M | -17.1M | -13.3M | -29.8M |
| EPS | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 | -0.02 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 2.87M | 7.26M | 4.94M | 10.4M | 9.42M | 16.5M | 17.8M | 32.1M | 91.2M | 58.6M |
| Total Liabilities | 242K | 407K | 738K | 2.63M | 7.95M | 2.07M | 11.8M | 13.9M | 77.8M | 73.3M |
| Shareholders' Equity | 2.63M | 6.86M | 4.20M | 7.76M | 1.47M | 14.4M | 5.96M | 18.2M | 13.4M | -14.8M |
| Cash & Short-term Investments | 2.24M | 6.28M | 3.56M | 7.79M | 5.25M | 9.63M | 7.99M | 22.1M | 68.3M | 16.2M |
| Total Debt | - | - | 1.09M | 1.06M | 5.09M | 73.1K | 5.96M | 150K | 97.5K | 232K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.86M | -3.23M | -2.75M | -4.72M | -6.46M | -13.4M | -12.7M | -7.00M | 39.1M | -51.8M |
| Capital Expenditure | 2.58K | 3.54K | 6.91K | 9.57K | 9.57K | 10.6K | 2.30K | 15.8K | 21.0K | 4.98K |
| Free Cash Flow | -1.87M | -3.23M | -2.76M | -4.72M | -6.47M | -13.4M | -12.7M | -7.02M | 39.0M | -51.8M |
| Ratios | ||||||||||
| ROE | -66.9% | -48.4% | -68.7% | -57.9% | -433.9% | -72.7% | -231.5% | -93.9% | -99.0% | - |
| ROA | -61.3% | -45.7% | -58.4% | -43.3% | -67.6% | -63.6% | -77.7% | -53.2% | -14.5% | -50.9% |
| Net Profit Margin | -317.2% | -392.8% | -199.4% | -192.0% | -143.5% | -162.3% | -37,521.4% | -2,926.4% | -1,056.3% | -685.3% |
| Debt to Equity | - | - | 0.26x | 0.14x | 3.47x | 0.01x | 1.00x | 0.01x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dimerix Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 24, 1999
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 10.7M | 0.03 | - |
| 2022 | AUD 1.40K | 0.00 | - |
| 2021 | AUD 1.24M | 0.01 | - |
| 2020 | AUD 8.48M | 0.05 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 23, 2017.
Who owns Dimerix Ltd
- Insiders 22.23%
- Institutions 2.96%
- Public & others 74.81%
- Shares outstanding 600M
- Free float 464M
Dimerix Ltd company profile
- Company name
- Dimerix Ltd
- Ticker
- DXB.AU
- ISIN
- AU000000DXB7
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- June
- Address
- 425 Smith Street, Fitzroy, VIC, Australia, 3065
- Phone
- 1300 813 321
- Website
- dimerix.com
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Dimerix Ltd management
4- Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D.CEO, MD & Director
- Dr. Robert ShepherdChief Operating Officer
- Dr. David Everett Fuller BPharm, M.D., MBBSChief Medical Officer · born 1964
- Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.Chief Scientific Advisor